FDA Drugs (New Approvals & NDA)Original article
Glenmark Pharmaceuticals Limited - 637314 - 09/23/2026
RegulatoryNegative
AI Analysis
Summary
Glenmark Pharmaceuticals Limited received an FDA regulatory notice related to CGMP and adulterated finished pharmaceuticals (reference 637314). The nature and implications of this regulatory action are not detailed in the source material.
Outcome Details
CGMP/Finished Pharmaceuticals/Adulterated
Importance:5/10
Sentiment:
-0.70
FDACGMPadulterationregulatorycompliance
Read the original article
Published by FDA Drugs (New Approvals & NDA) on October 5, 2026 6:00 PM